#WuXi XDC #GMP Release #Singapore Site

WuXi XDC Celebrates GMP Release of Singapore Site

On September 21, 2026, WuXi XDC Cayman Inc., a prominent global player in Contract Research, Development and Manufacturing Organization (CRDMO), proudly marked the GMP (Good Manufacturing Practice) release of its new manufacturing site located at Tuas Biomedical Park, Singapore. This momentous occasion not only signifies a major step in WuXi XDC's global expansion efforts but also demonstrates a swift execution of its ambitious vision set forth in March 2024 when the site was first announced.

The Singapore facility, encompassing a sprawling 25,000 square meters, is now equipped with sophisticated production lines designed to facilitate the manufacturing of bioconjugates, an area WuXi XDC is actively developing. With the successful attainment of GMP release for the BCM3 antibody intermediate and conjugated drug substance dual-function production line, alongside the DP4 facility's readiness, WuXi XDC has transitioned from a conceptual roadmap to concrete results in just two and a half years.

Importance of the GMP Release

The GMP release is not merely a procedural milestone; it marks the company's commitment to enhancing the resilience and diversification of its global supply chain in the bioconjugate sector. Dr. Jimmy Li, CEO of WuXi XDC, expressed the significance of this achievement in his opening speech at the ceremony. He emphasized that this marks the advent of a “Global Dual-Sourcing” strategy, enabling clients worldwide to accelerate their commercial manufacturing processes by utilizing advanced and synchronized facilities located both in Singapore and WuXi.

Furthermore, the release reflects the strong collaboration between WuXi XDC and various industry stakeholders. Ms. Cindy Koh, Executive Vice President of the Singapore Economic Development Board (EDB), praised the decisiveness in strengthening Singapore’s capability in manufacturing complex biopharmaceutical modalities, echoing WuXi XDC's trust in Singapore as a reliable biopharmaceutical hub.

Advanced Production Capabilities

The operational landscape of the Singapore site is characterized by its state-of-the-art technology and stringent adherence to international GMP standards, including those set forth by FDA, EMA, and NMPA. The BCM3 line is designed to provide an efficient